Caricamento...
Both cladribine and alemtuzumab may effect MS via B-cell depletion
OBJECTIVE: To understand the efficacy of cladribine (CLAD) treatment in MS through analysis of lymphocyte subsets collected, but not reported, in the pivotal phase III trials of cladribine and alemtuzumab induction therapies. METHODS: The regulatory submissions of the CLAD Tablets Treating Multiple...
Salvato in:
| Pubblicato in: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Lippincott Williams & Wilkins
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5459792/ https://ncbi.nlm.nih.gov/pubmed/28626781 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000360 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|